HOME >> MEDICINE >> NEWS
Wartime raises stress, blood pressure rates in military offspring

Children with parents in the military have higher blood pressure, heart rates and general stress levels than their peers during wartime, researchers say.

Researchers looked at 121 adolescents including 48 with civilian parents, 20 with a parent deployed to Iraq and 53 with a parent in the military but not deployed days after Operation Iraqi Freedom was launched in March 2003 and nearly three months later when President Bush announced major hostilities had ceased.

At both points, adolescent offspring of military personnel self-reported higher levels of stress and measures of blood pressure and heart rates supported that.

"We expected stress levels would push up blood pressure and heart rates," says Dr. Vernon Barnes, physiologist at the Medical College of Georgia and principal author of a paper published in the January issue of Military Medicine.

Dr. Barnes and his colleagues used a posttraumatic stress disorder questionnaire developed by the military for personnel and modified for adolescents, a survey to assess psychosocial concerns such as sense of well-being and faith in government as well as more objective heart rate and blood pressure measures.

Not surprisingly, they found that particularly adolescents with deployed parents had higher rates than their classmates. Studies were done at the Academy of Richmond County, a high school in Augusta, Ga., attended by many children whose parents are stationed at Fort Gordon.

Acknowledging that the study size was small and did not assess non-war related stressors, the researchers note that the physical impact of the war on military offspring merits attention. "We are not aware of any studies examining the impact of the onset of the war on both stress levels and blood pressure of military offspring," Dr. Barnes says.

There is evidence of the impact of environmental stress on blood pressure and heart rate, important indicators of cardiovascular hea
'"/>

Contact: Toni Baker
tbaker@mcg.edu
706-721-4421
Medical College of Georgia
9-Feb-2007


Page: 1 2

Related medicine news :

1. Study raises new treatment possibilities for cognitive disorders
2. Having elevated risk factors in young adulthood raises risk of coronary calcium later on
3. Major discovery raises prospect of better patient care by improving platelet life span
4. Improved treatment raises medulloblastoma survival rate
5. Supertron raises $3.5 million in Series C Financing
6. Stopping medication too soon after receiving a drug-eluting stent raises risk of death
7. Selenium-protein deficiency raises prostate cancer risk
8. Childhood arthritis raises risk of broken bones
9. Rapid lung function decline raises risk of death and hospitalization
10. New research shows second-hand smoke raises diabetes risk
11. Obesity in middle age raises heart disease, diabetes risk in older age

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Wartime raises stress blood pressure rates military offspring

(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. 21, 2014 (HealthDay ... (IVF) -- the incubation of embryos in a laboratory dish ... vagina, new research suggests. Scientists from the United States ... sharply cut costs for pricey IVF procedures among certain women. ... who don,t live near big-city assisted reproduction centers, the researchers ...
(Date:10/22/2014)... Dennis Thompson HealthDay Reporter ... officials on Monday officially tightened guidelines for health workers treating ... exposure and use of a respirator at all times. ... issue the tougher rules after two Dallas nurses contracted Ebola ... United States, Liberian national Thomas Eric Duncan. Nina Pham is ...
(Date:10/20/2014)... Dallas, Texas (PRWEB) October 20, 2014 ... is the must-have source of thousands of facts, figures ... 72 countries and 68 medical sector forecast categories the ... you with global, regional and national views on the ... future outlook. , The report gives you data for ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Allegheny General ... procedure that enables physicians to repair a damaged mitral ... MitraClip system, developed by Abbott Vascular ... a progressive and life-threatening condition in which the heart’s ... to flow backward from the heart’s left ventricle into ...
(Date:10/20/2014)... ASCNYC (ascnyc.org) is a New ... Yorkers living with HIV/AIDS and other chronic conditions ... and self-sufficiency. Each year, ASCNYC spotlights selected “Positive ... their tireless efforts. , Savills Studley ... been selected as this year’s honoree for sharing ...
Breaking Medicine News(10 mins):Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3
(Date:10/22/2014)...   Surefire Medical , Inc., the developer of ... targeted delivery of embolization agents in minimally invasive direct-to-tumor ... John R. Daniels , MD of the University of ... Steven C. Katz , MD of the Roger ... Board (SAB).    "The role of the ...
(Date:10/22/2014)... and AUSTIN, Texas ... and PureMHC LLC today announced they have entered ... novel antibody-based immunotherapies designed to target cancers. ... phosphorylated peptides displayed on the surfaces of tumor ... tumor targets (PTTs), derived from proteins that play ...
(Date:10/22/2014)... , Oct. 22, 2014  Regulus ... a biopharmaceutical company leading the discovery and ... announced that it has demonstrated human proof-of-concept ... clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated ... of hepatitis C virus infection ("HCV").  Interim ...
Breaking Medicine Technology:Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8
Cached News: